BioDelivery Sciences International Inc
F:BD5
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
BioDelivery Sciences International Inc
Other Long-Term Assets
BioDelivery Sciences International Inc
Other Long-Term Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Long-Term Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
B
|
BioDelivery Sciences International Inc
F:BD5
|
Other Long-Term Assets
$56.5m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Other Long-Term Assets
$19.3B
|
CAGR 3-Years
3%
|
CAGR 5-Years
8%
|
CAGR 10-Years
7%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Other Long-Term Assets
$8.2B
|
CAGR 3-Years
42%
|
CAGR 5-Years
20%
|
CAGR 10-Years
8%
|
|
|
|
Pfizer Inc
NYSE:PFE
|
Other Long-Term Assets
$19.3B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
28%
|
CAGR 10-Years
14%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Other Long-Term Assets
$17.8B
|
CAGR 3-Years
30%
|
CAGR 5-Years
13%
|
CAGR 10-Years
11%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Other Long-Term Assets
$17B
|
CAGR 3-Years
33%
|
CAGR 5-Years
22%
|
CAGR 10-Years
23%
|
|
BioDelivery Sciences International Inc
Glance View
BioDelivery Sciences International, Inc. operates as a pharmaceutical company, which engages in the development and commercialization of new applications of approved therapeutics to address important unmet medical needs. The company is headquartered in Raleigh, North Carolina and currently employs 200 full-time employees. The company went IPO on 2002-06-25. The firm focuses on delivering therapies for individuals living with serious and debilitating chronic conditions. The Compnay builts a portfolio of products that includes utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA), drug-delivery technology to develop and commercialize new applications of therapies aimed at addressing important unmet medical needs. BEMA drug delivery technology consists of a small, bi-layered erodible polymer film for application to the buccal mucosa (the lining inside the cheek). The firm's product candidates includes BELBUCA (buprenorphine buccal film), CIII, for Chronic Pain; Symproic (naldemedine), for Opioid Induced Constipation and ONSOLIS (fentanyl buccal soluble film) for Breakthrough Cancer Pain.
See Also
What is BioDelivery Sciences International Inc's Other Long-Term Assets?
Other Long-Term Assets
56.5m
USD
Based on the financial report for Dec 31, 2021, BioDelivery Sciences International Inc's Other Long-Term Assets amounts to 56.5m USD.
